Phosphagenics appoints pharma veteran
By Dylan Bushell-Embling
Tuesday, 08 July, 2008
Tuesday, 08 July, 2008
Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.
Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.
Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.
Ashton also served as CEO for SkyePharma PLC.
Related News
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
